RDEA3170 Monotherapy in Subjects With Gout

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01927198
Recruitment Status : Completed
First Posted : August 22, 2013
Last Update Posted : July 1, 2015
Information provided by (Responsible Party):
Ardea Biosciences, Inc.

Brief Summary:
This study will assess the serum uric acid lowering effects and safety of 3 dose levels of RDEA3170 compared to placebo in subjects with gout.

Condition or disease Intervention/treatment Phase
Gout Drug: Placebo Drug: RDEA3170 5 mg Drug: RDEA3170 10 mg Drug: RDEA3170 12.5 mg Phase 2

Detailed Description:
This monotherapy study is the initial Phase 2 study for RDEA3170 and is designed to compare the safety and efficacy of multiple dose levels of RDEA3170 with placebo when given for up to 24 weeks to subjects with gout. The placebo control for RDEA3170 is included in this study to minimize bias in study assessments and monitoring. Further, to accomplish the goal of understanding the safety profile of RDEA3170, it is important to compare RDEA3170 monotherapy with placebo for at least 24 weeks.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 172 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of RDEA3170 Monotherapy in Subjects With Gout
Study Start Date : August 2013
Actual Primary Completion Date : May 2014
Actual Study Completion Date : July 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Gout

Arm Intervention/treatment
Experimental: RDEA3170 5 mg qd
No titration.
Drug: RDEA3170 5 mg
Experimental: RDEA3170 10 mg qd
Increase from RDEA3170 5 mg to RDEA3170 10 mg qd at Week 2.
Drug: RDEA3170 10 mg
Experimental: RDEA3170 12.5 mg qd
Increase from RDEA3170 10 mg to RDEA3170 12.5 mg qd at Week 4.
Drug: RDEA3170 12.5 mg
Placebo Comparator: Placebo
Placebo group
Drug: Placebo

Primary Outcome Measures :
  1. Efficacy of RDEA3170 monotherapy at Week 12 [ Time Frame: Week 12 ]
    Percent change from baseline in serum urate levels at Week 12.

Secondary Outcome Measures :
  1. Incidence of treatment-emergent adverse events and change from baseline in laboratory values, vital signs, and electrocardiograms [ Time Frame: 8 months ]
    Safety assessments include adverse event (AE) recording, gout flare recording, clinical safety laboratory tests (eg, hematology, serum chemistry, and urinalysis), physical examinations, vital sign measurements, and ECGs.

  2. Efficacy of RDEA3170 monotherapy at Week 24 [ Time Frame: Week 24 ]
    Percent change from baseline in serum urate levels at each visit. Proportion of subjects with a serum urate level < 6.0 and < 5.0 mg/dL at each visit.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject meets the diagnosis of gout per the American Rheumatism Association Criteria for the Classification of Acute Arthritis of Primary Gout.
  • Subject has a serum urate level ≥ 6.5 mg/dL and ≤ 10.0 mg/dL during the Screening Period.
  • Subject has a body mass index < 40 kg/m2.

Exclusion Criteria:

  • Subject is pregnant or breastfeeding. Subject consumes more than 14 drinks of alcohol per week (eg, 1 drink = 5 oz [150 mL] of wine, 12 oz [360 mL] of beer, or 1.5 oz [45 mL] of hard liquor).
  • Subject has a history or suspicion of kidney stones.
  • Subject has a history or suspicion of drug abuse within the past 5 years.
  • Subject has a history of symptomatic myositis/myopathy or rhabdomyolysis.
  • Subject has a known or suspected human immunodeficiency virus infection.
  • Subject has a positive test for active hepatitis B or hepatitis C infection.
  • Subject has a history of malignancy within the previous 5 years with the exception of non-melanoma skin cancer that has been treated with no evidence of recurrence, treated cervical dysplasia, or treated in situ Grade 1 cervical cancer.
  • Subject within the last 12 months with: unstable angina, New York Heart Association class III or IV heart failure, myocardial infarction, stroke, or deep venous thrombosis; or subjects currently receiving anticoagulants.
  • Subject has a QT interval corrected for heart rate according to Fridericia's formula > 450 msec during the Screening Period, confirmed by a repeat assessment.
  • Subject has uncontrolled hypertension.
  • Subject has an estimated creatinine clearance < 60 mL/min.
  • Subject has an alkaline phosphatase > 2.0 x upper limit of normal during the Screening Period.
  • Subject has active liver disease or impaired hepatic function.
  • Subject is receiving chronic treatment with more than 325 mg salicylates per day.
  • Subject has a medical condition that requires or may require systemic immunosuppressive (eg, chronic low-dose oral prednisone) or immunomodulatory treatment.
  • Subject is unable to take colchicine for gout flare prophylaxis.
  • Subject is receiving strong or moderate CYP3A inhibitors, p-glycoprotein inhibitors, or digoxin.
  • Subject received any strong enzyme- inducing drug or product (eg, rifampin, rifabutin, phenytoin, phenobarbital, St. John's Wort) within 2 months prior to Day 1 or refuses to refrain from taking these medications until the end of the study.
  • Subject received an investigational therapy within 30 days or 5 half-lives (whichever is longer) prior to the Screening Period.
  • Subject has any other medical or psychological condition, which in the opinion of the Investigator and/or Medical Monitor, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements, or to complete the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01927198

  Show 50 Study Locations
Sponsors and Collaborators
Ardea Biosciences, Inc.
Study Director: J. Hall, MD Ardea Biosciences, Inc.

Responsible Party: Ardea Biosciences, Inc. Identifier: NCT01927198     History of Changes
Other Study ID Numbers: RDEA3170-201
First Posted: August 22, 2013    Key Record Dates
Last Update Posted: July 1, 2015
Last Verified: June 2015

Additional relevant MeSH terms:
Joint Diseases
Musculoskeletal Diseases
Crystal Arthropathies
Rheumatic Diseases
Purine-Pyrimidine Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases